Company: LCTX
Filing Date: 2025-06-11
Form Type: DEFA14A
Source: 0000950170-25-084916
Chunk: 1

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-06-11
Form: DEFA14A
Chunk 1
---
 Committee”) selected Moss Adams LLP (“Moss Adams”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2025. On June 3, 2025, we were notified that Moss Adams merged with Baker Tilly US, LLP (“Baker Tilly”), effective on June 3, 2025, and that the combined audit practices operate as Baker Tilly. In connection with the notification of the merger, Moss Adams resigned as our independent registered public accounting firm and the Audit Committee approved the appointment of Baker Tilly, as the successor to Moss Adams, as our independent registered public accounting firm for the fiscal year ending December 31, 2025. As reported in the Current Report on Form 8-K we filed with the SEC on June 9, 2025 (the “Auditor Change 8-K”), the audit report of Moss Adams on our consolidated financial statements for the year ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles. During the year ended December 31, 2024, and from December 31, 2024 through June 3, 2025, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between us and Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Moss Adams, would have caused Moss Adams to make reference to the subject matter of such disagreements in connection with its report, or (ii) “reportable events,” as described in Item 304(a)(1)(v) of Regulation S-K, that would require disclosure under Item 304(a)(1)(v) of Regulation S-K. During our two most recent fiscal years and from December 31, 2024 through June 3, 2025, neither we, nor any person acting on our behalf, consulted Baker Tilly regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of the audit opinion that might be rendered on our financial statements, and Baker Tilly did not provide any written report or oral advice to us that Baker Tilly concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or